NasdaqGS:TSHABiotechs
Should Rett Breakthrough Status and Pivotal Trial Plan Require Action From Taysha Gene Therapies (TSHA) Investors?
Taysha Gene Therapies recently received FDA Breakthrough Therapy Designation for its Rett syndrome gene therapy candidate TSHA-102 and secured regulatory alignment on the pivotal REVEAL trial protocol, including a planned six-month interim analysis to support a future Biologics License Application.
This combination of regulatory recognition and a clearly defined clinical pathway adds important validation to TSHA-102’s potential and clarifies how quickly the Rett program could progress toward...